| 111.7 3.05 (2.81%) | 11-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 132.43 |
1-year : | 154.68 |
| Resists | First : | 113.38 |
Second : | 132.43 |
| Pivot price | 105.16 |
|||
| Supports | First : | 105.16 |
Second : | 100.08 |
| MAs | MA(5) : | 106.38 |
MA(20) : | 105.44 |
| MA(100) : | 106.26 |
MA(250) : | 107.34 |
|
| MACD | MACD : | 0.9 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 76.6 |
D(3) : | 57.7 |
| RSI | RSI(14): 68.7 |
|||
| 52-week | High : | 129.27 | Low : | 81.19 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BNTX ] has closed Bollinger Bands are 12.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 110.15 - 110.67 | 110.67 - 111.15 |
| Low: | 103.61 - 104.22 | 104.22 - 104.76 |
| Close: | 107.64 - 108.65 | 108.65 - 109.56 |
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Wed, 12 Nov 2025
A Closer Look at BioNTech's Options Market Dynamics - Benzinga
Wed, 12 Nov 2025
BioNTech Unveils Strategic Advances at R&D Day 2025 - TipRanks
Wed, 12 Nov 2025
BIONTECH : Jefferies reiterates its Buy rating - MarketScreener
Tue, 11 Nov 2025
What BioNTech (BNTX)'s Raised 2025 Revenue Guidance Means for Shareholders - simplywall.st
Tue, 11 Nov 2025
BioNTech’s Impressive Q3 Performance: What’s Next? - timothysykes.com
Tue, 11 Nov 2025
BioNTech price shows more positive signs - Forecast today - 11-11-2025 - Economies.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 240 (M) |
| Shares Float | 94 (M) |
| Held by Insiders | 62.6 (%) |
| Held by Institutions | 23 (%) |
| Shares Short | 6,180 (K) |
| Shares Short P.Month | 6,380 (K) |
| EPS | -1.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 76.98 |
| Profit Margin | -12 % |
| Operating Margin | -167.5 % |
| Return on Assets (ttm) | -2.2 % |
| Return on Equity (ttm) | -1.9 % |
| Qtrly Rev. Growth | 102.5 % |
| Gross Profit (p.s.) | 9.56 |
| Sales Per Share | 11.97 |
| EBITDA (p.s.) | -2.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1,740 (M) |
| Levered Free Cash Flow | -2,390 (M) |
| PE Ratio | -67.29 |
| PEG Ratio | 0 |
| Price to Book value | 1.45 |
| Price to Sales | 9.32 |
| Price to Cash Flow | -15.44 |
| Dividend | 2.1 |
| Forward Dividend | 0 |
| Dividend Yield | 1.8% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|